Home >

Early Diagnosis Of Lung Cancer By Fluid Biopsy Of AI Tumor?

2021/4/7 13:56:00 0

AITumorFluidBiopsyLesionLung Cancer

"The popularization of liquid biopsy and artificial intelligence will greatly improve the diagnostic ability of pulmonary nodules. In the future, with the establishment of standardized path for lung cancer screening and early diagnosis, it can further promote the advancement of lung cancer prevention and treatment port in China, greatly optimize the use of medical resources, and greatly improve the survival rate of lung cancer. " Recently, Bai Chunxue, chairman of the China lung cancer prevention and treatment alliance and professor of Sun Yat Sen Hospital of Fudan University, said in an interview with the reporter of the 21st century economic report.

As early as 2008, Bai Chunxue put forward the concept of Internet of things, combining artificial intelligence with CT and CAC (abnormal cells in blood circulation). The clinical data of China's multicenter led by Bai Chunxue show that the accuracy rate of CAC + ct.ai in the diagnosis of pulmonary nodules can reach 85% ~ 90%.

Anxin Securities pointed out that the traditional tumor screening has the defects of strong invasion, poor sensitivity and low compliance. As a new non-invasive detection technology, liquid biopsy has the advantages of noninvasive, efficient, accurate and dynamic monitoring.

Lu Hai, managing director of SDIC investment promotion, also said that he was optimistic about the track of tumor liquid biopsy for a long time, because it can bring more benefits to tumor patients and doctors. It is simple, easy to repeat and suitable for all patients. The results can be obtained without tissue biopsy. Based on the market capacity and huge unmet demand, recently, SDIC also led the investment of shengmei biological round B financing.

Blue ocean

Before 2000, the liquid biopsy industry was in the exploratory stage. Biomarkers such as CTC and ctDNA were found in the research, and the first generation of CTC detection technology was invented. After 2000, the sensitivity of liquid biopsy has been gradually improved, mature CTC detection system and ctDNA detection products have been approved by the authority, and the liquid biopsy industry has initially developed.

In 2015, liquid biopsy was selected as the top ten breakthrough technologies of MIT review of technology.

After 2016, the clinical application value of liquid biopsy has gradually been recognized, and a number of liquid biopsy related products have obtained regulatory approval, accelerating the market-oriented development of liquid biopsy industry.

In recent years, China is also encouraging the development of liquid biopsy, and has issued a number of relevant supporting policies, including supporting the development and application of relevant technologies, accelerating the approval speed, etc.

In China, the field of liquid biopsy is developing rapidly, and a number of liquid biopsy related products have been approved for marketing. In April 2016, liquid biopsy technology was first written into the Chinese Medical Association guidelines for diagnosis and treatment of lung cancer. In August 2016, CTC staining kit produced by youzhiyou company was approved to be on the market to detect the amount of CTC in human peripheral blood; in January 2018, the super arms? EGFR gene mutation detection kit developed by aide bio became the first ctDNA detection kit approved by the State Food and drug administration to accompany the evaluation of diagnostic reagent standards.

For China's liquid biopsy market, securities companies and other institutions are optimistic. CICC Qixin international consulting pointed out that in 2026, the global market capacity of generalized liquid biopsy in China is about 32.6 billion US dollars, including 28.6 billion US dollars in cancer field.

According to the analysis of the head and leopard Research Institute, the compound annual growth rate of China's liquid biopsy market is 19.4%. The reason for the gradual growth of this market is mainly due to the unique technical advantages of liquid biopsy, wide range of indications, and increasing demand for tumor diagnosis and treatment.

For example, compared with tissue biopsy, liquid biopsy can collect samples noninvasively, monitor tumor development in real time, and effectively overcome tumor specificity. As an innovative diagnostic technology, liquid biopsy has significant application advantages; clinical trials of liquid biopsy have a wide range of indications, including lung cancer, gastric cancer, prostate cancer, breast cancer, colorectal cancer, leukemia and other tumors and musculoskeletal Detection of more than 20 cancers and diseases such as systemic and connective tissue diseases.

Shi Jianfeng, general manager of shengmei biology, who has studied diagnostic reagents for many years, pointed out to the reporter of 21st century economic report that from the perspective of clinical application, liquid biopsy can be applied in all stages of tumor treatment, including early auxiliary diagnosis of tumor, guidance of clinical medication, concomitant diagnosis of targeted drugs, and real-time efficacy monitoring.

As mentioned above, the aide biological ctDNA detection kit is deeply bound with the AstraZeneca targeted drug oxitinib, which is used for clinical detection of EGFR gene mutation status in blood ctDNA of patients with advanced non-small cell lung cancer (NSCLC). It can screen patients who are suitable for the treatment of first to third generation EGFR targeted drugs.

The growth of tumor diagnosis and treatment demand directly drives the development of liquid biopsy market and its technical application. In early 2021, the World Health Organization released the latest global cancer data, which showed that in 2020, there were 19.29 million new cancer cases in the world, including 4.57 million new cancer cases in China, accounting for 23.7% of the world,

According to the Chinese guidelines for screening, early diagnosis and treatment of lung cancer (2021, Beijing) (hereinafter referred to as the guidelines), the incidence and mortality of lung cancer are the first among all malignant tumors. From 2000 to 2011, the total number of lung cancer cases and deaths in Chinese men and women showed a continuous increase trend. According to the data of GLOBOCAN 2020, the incidence and death of lung cancer in China account for 37.0% and 39.8% of the world respectively. Lung cancer prevention and control is a major challenge for cancer prevention and control in China.

Bai Chunxue pointed out to the reporter of the 21st century economic report that the survival time of lung cancer patients is closely related to the time of diagnosis. The data quoted in the guide show that the 5-year survival rate of lung cancer decreases with the increase of diagnosis stage. The 5-year survival rate of stage I was 55.5%, while that of stage IV was 5.3%.

There are nearly 800000 new lung cancer patients in China every year. 75% of lung cancer patients have been diagnosed as stage III - IV, and the 5-year survival rate is less than 20%. For the problem of low survival rate, Bai Chunxue explained that the main reason is that early lung cancer often appears as asymptomatic pulmonary nodules. The existing diagnosis and treatment technology is difficult to make timely and accurate diagnosis of small pulmonary nodules (> 10 mm nodules), resulting in over treatment or delayed diagnosis and loss of the best treatment opportunity.

"A large number of trials have confirmed that low-dose spiral computed tomography (LDCT) can reduce lung cancer mortality by 20%. However, the false positive rate of pulmonary nodules has increased significantly. Whether patients with pulmonary nodules need further detection is the core problem faced by clinicians Bai Chunxue told the 21st century economic reporter.

In the early screening of lung cancer, lung nodules are often found in imaging examination. Pulmonary nodules are round or irregular lesions with a diameter of less than 3cm, which can be divided into benign and malignant ones. Malignant nodules are lung cancer.

Tang Dongjiang, deputy general manager of shengmei biological research and development, told reporters of the 21st century economic report that the current identification methods of pulmonary nodules mainly include PET-CT, percutaneous puncture biopsy and bronchoscopy biopsy, but there are also their own shortcomings.

For example, PET-CT has no obvious advantage in differential diagnosis of pulmonary nodules ≤ 8mm, For larger nodules, there is a certain risk of false negative; percutaneous puncture biopsy is invasive invasive, with side effects such as bleeding, pneumothorax, lung collapse, etc., and there is a risk of false negative for small nodules; bronchoscopy has certain requirements for the location of nodules, and most pulmonary nodules cannot be directly reached by bronchoscopy, which also has a high risk of false negative.

Fluid biopsy AI "+"

Anxin securities also pointed out that liquid biopsy, as a new non-invasive detection technology, has the advantages of convenient sampling and dynamic monitoring. At present, the main biomarkers of tumor origin in liquid biopsy are circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVS) and circulating RNA.

However, these biomarkers have different applications in different cancers. For example, CTCs are mainly targeted at patients with advanced lung cancer, which can be judged by detecting the expression of specific antigen on the cell surface. The main pain point of CTCS detection lies in the difficulty of capture and recognition.

CtDNA detection can provide personalized disease detection scheme, which has higher sensitivity in early cancer detection. Anxin securities, liquid biopsy technology based on ctDNA mutation (base mutation) has obvious defects. The detection limit of gene mutation detection based on deep sequencing is 0.1% - 0.5%.

However, studies related to nature found that the ctDNA concentration of early patients with 25px3 tumor is generally about 0.008%, which is an order of magnitude difference with the detection ability of gene mutation, which is also the pain point of liquid biopsy technology based on ctDNA mutation in early cancer screening.

Tang Dongjiang also pointed out to the 21st century economic reporter that the amount of tumor related DNA released in the blood is too small to be captured by PCR technology, second-generation sequencing technology and digital PCR technology.

However, there are new breakthroughs in CAC research. Ruth, former director of Department of cell pathology, Anderson Cancer Center, USA, 2020 50. In cancer cell pathology, an official journal of the American Cancer Association, Professor Katz further revealed the distribution difference of CAC in peripheral blood of patients with benign and malignant pulmonary nodules, and explored the potential value of CAC detection based on 4-color fluorescence in situ hybridization in early diagnosis, risk stratification and diagnosis and treatment decision-making of lung cancer.

It is understood that the detection and evaluation of CAC is noninvasive, real-time and dynamic monitoring, can overcome the heterogeneity of tumor, and can provide comprehensive detection information, and the detection results are not affected by tumor size, pathological type and nodule nature. It can be an ideal early diagnosis auxiliary detection method for the differentiation of benign and malignant pulmonary nodules of 5 ~ 10 mm.

At an industry forum, Professor Huang Qihong, researcher of Zhongshan Hospital, discussed in detail the role and challenges of "liquid biopsy" in the diagnosis and treatment of lung cancer. He pointed out that liquid biopsy is the fastest developing non-invasive detection technology in recent years. He also compared and summarized the commonly used liquid biopsy methods in the world and their shortcomings in practical application, and advocated that liquid biopsy should be applied in the diagnosis and treatment of lung cancer The combination of biopsy and other medical detection techniques will contribute to the early diagnosis of cancer.

Bai Chunxue is also trying to combine CT, artificial intelligence intervention and liquid biopsy. Combined with artificial intelligence, CAC can realize the functions of disease detection and location, qualitative analysis, benign and malignant judgment and postoperative follow-up, which can help doctors to achieve fast, accurate and intelligent film reading. Chinese multicenter clinical data led by Professor Bai Chunxue show that the accuracy of CAC + ct.ai in the diagnosis of pulmonary nodules can reach 85% ~ 90%.

Bai Chunxue introduced to the 21st century economic report that the China lung cancer prevention and control alliance will start the "intelligent benefit million early lung cancer project" to better play the role of AI in the diagnosis and treatment of early lung cancer. In 2021, it will start 30 "Ai diagnosis and treatment sub centers of lung nodules of China lung cancer prevention and control alliance", which will increase to 100 within three years, with the target sensitivity of 99% and specificity of more than 95%. One million patients with early lung cancer were treated within 10 years, and the 10-year survival rate was more than 90%.

It is also understood that in order to solve the flux bottleneck and standardization caused by the mass cell images of liquid biopsy, shengmei bio creatively applied high-throughput automatic image scanning and cytological artificial intelligence analysis in the field of tumor liquid biopsy, and developed the "hardware platform for tumor fluid biopsy cell analysis + artificial intelligence analysis system for tumor fluid biopsy cells", and passed the "early diagnosis of cancer" "Intelligent overall solution" provides multi-dimensional clinical test data and medical diagnosis services for doctors and patients around the world.

"As the first liquid biopsy technology to achieve a commercial breakthrough, shengmei biological has built a cloud platform connecting doctors, patients and detection terminals, and supported artificial intelligence technology. Through big data analysis, it can assist clinical diagnosis or provide accurate risk stratification for high-risk groups of lung cancer, especially after nodules are found by low-dose spiral CT The follow-up period of Tang Dongjiang said.

Among them, shengmei biological liquidbiopsy is the only enrichment and separation platform of circulating tumor cells (CTC) that can directly connect with downstream multiple molecular detection. CAC detection technology is the only leading technology in the world to realize the differentiation of benign and malignant pulmonary nodules through abnormal circulation cells (CAC).

However, Tang Dongjiang still stressed that "the use of artificial intelligence to drive tumor fluid biopsy" can be more accurately diagnosed through the combination of biology, big data and artificial intelligence, not based on a single indicator, and its development still has a long way to go.

 

  • Related reading

New Technology: UK Launches New Textile Material Lean Ball

Innovation and invention
|
2021/3/28 22:33:00
4

SMIC International Takes The Lead In Expanding Wafer Production Capacity And Predicts "Core Shortage" Throughout 2021

Innovation and invention
|
2021/3/19 9:39:00
8

Sustainable Polyethylene Textile Fabrics Come Out

Innovation and invention
|
2021/3/17 11:17:00
3

Carbon Emission Quota Marketization: Cement Industry Is Expected To Give Priority To National Carbon Trading

Innovation and invention
|
2021/3/17 11:11:00
3

Innovation: The Great Potential Of Electronic Textiles Made From New Cellulose Fibers

Innovation and invention
|
2021/3/15 12:32:00
9
Read the next article

The Merger Of The Two Boards And The Formal Implementation Of "Shenzhen Main Board"

The original SME board "002001-004999" securities code range is used by the main board, the original SME board index, SME board composite index, SME board 3